Genetics of Cancer Predisposition: Is Destiny Written In The DNA?

Knowing our genetic risks means rewriting what was once seen as destiny. From uncertainty, we are moving toward awareness and prevention, and turning generations of loss into a future of hope

Family photo albums tell stories of birthdays under warm lights, weddings filled with laughter, children with mischievous smiles. Yet, between those joyful snapshots lie quieter memories we rarely speak of — an aunt lost too soon to breast cancer, a grandfather whose illness no one understood, a mother who fought bravely but could not win. Back then, people would sigh, “It was fate.” Doctors did their best, families held on to faith, but there was a helplessness in not knowing why cancer seemed to strike some families again and again.

Today, that silence is giving way to understanding. The same DNA that carried those unspoken stories now holds the clues we once searched for in prayer and chance. Genomics, the study of our entire genetic blueprint, is revealing that cancer is not always a random visitor. Sometimes, it runs through generations, hidden in the folds of inheritance. But this is not a story of fear; it is one of foresight. Knowing our genetic risks means rewriting what was once seen as destiny. From uncertainty, we are moving toward awareness and prevention, and turning generations of loss into a future of hope.

How cancer genetics began

Understanding hereditary cancer did not start with modern sequencers or high-tech labs. It started with careful observation, statistics, and questions about patterns in families. In the 1970s, Alfred Knudson, a statistician and physician, studied retinoblastoma, a rare childhood eye cancer. He noticed a fascinating pattern: children with inherited forms of the disease developed tumors earlier, often in both eyes, while sporadic cases appeared later and only in one eye.

Knudson proposed the two-hit hypothesis, a concept that remains central to cancer genetics today. According the hypothesis, the first hit is inherited. In this, some people inherit a faulty copy of a tumor suppressor gene from a parent. These genes normally act as “brakes” to stop cells from growing uncontrollably. The second hit is acquired — a random mutation in the remaining healthy copy of that gene in a specific cell cam trigger cancer.

This insight explained why inherited predispositions do not guarantee disease, they only increase susceptibility. In other words, inheritance can set the stage, but the actual cancer requires another step, which may or may not occur.

How genes control cancer risk

Our cells are like tiny machines, and their growth and repair are tightly controlled. Three types of genes play key roles in cancer risk:

• Proto-oncogenes (the accelerator): These genes promote normal cell growth. When they mutate into oncogenes, it’s like a stuck accelerator cell grow uncontrollably
• Tumor suppressor genes (the brakes): Genes like TP53, known as the “guardian of the genome”, act as brakes. When they fail, cells ignore signals to stop dividing
• DNA repair genes (the mechanics): These genes detect and fix DNA mistakes. When defective, errors accumulate, making cells unstable and more likely to become cancerous
  

Think of it like driving a car: the accelerator pushes you forward, the brakes prevent crashes, and the mechanics keep the engine running smoothly. When one or more fails, accidents in this case, cancer become more likely.

High-risk syndromes: Clear but rare

Genetic risk for cancer exists on a spectrum, from rare but high-impact mutations to a subtle mix of many small changes in our DNA. Some inherited mutations greatly increase cancer risk:

• Lynch syndrome: Mutations in DNA mismatch repair genes cause errors to accumulate rapidly. People with Lynch Syndrome face higher risks for colorectal, uterine, and ovarian cancers
• Li-Fraumeni syndrome: Mutations in the TP53 gene increase the likelihood of multiple rare cancers, including sarcomas, brain tumors, and adrenal cancers, often at a young age
• Hereditary diffuse gastric cancer: Mutations in the CDH1 gene can lead to aggressive stomach cancer. In high-risk individuals, preventive surgery is sometimes recommended

These syndromes may account for only a small fraction of hereditary cancers, but they illustrate how knowledge of one gene can dramatically guide prevention and treatment.

Polygenic risk: Many small changes, big impact

For most people, cancer risk is influenced by many small variations in DNA, called single nucleotide polymorphisms (SNPs). Each variant has only a minor effect, but combined, they can significantly alter risk.

Polygenic risk scores (PRS) calculate the cumulative effect of these small variations. The scores can identify individuals at higher risk even if no single gene mutation is detected. For example, a person with no strong family history could still fall into the top 10% of risk, similar to someone with a moderate single-gene mutation.

This approach has transformed how we think about hereditary cancer. Instead of a binary “yes or no” risk, we now see a continuum, helping clinicians personalise screening and preventive strategies.

Why India needs its own genetic research

Much of our current understanding of cancer genetics comes from studies on European populations. India’s genetic diversity is vast, meaning many local mutations are not represented in global databases. Research has shown that cancer in Indian families often involves unique gene variants, some of which may not appear in Western testing panels.

Moreover, cancer in India often occurs at a younger age. While environmental and lifestyle factors contribute, genetic predisposition may accelerate disease onset. Without India-specific datasets, there is a risk of missing critical variants, giving false reassurance to patients.

Building a large Indian reference genome database and making testing accessible nationwide are essential. The goal is not just prediction, but action: early detection, personalised prevention, and better outcomes.

Turning knowledge into action

Knowing one’s genetic risk does not mean resignation. It provides a roadmap for prevention such as targeted screening, preventive surgery, medications, and testing family members.

In the case of targeted screening, high-risk individuals may start mammograms or colonoscopies earlier or use more sensitive imaging like MRI, while preventive surgery is for certain high-risk cases, were removal of at-risk organs, such as prophylactic mastectomy or oophorectomy, can dramatically reduce cancer risk. In certain high-risk individuals, preventive therapies, such as selective estrogen receptor modulators (e.g., tamoxifen) or aspirin for specific hereditary syndromes, can lower the likelihood of developing cancer. Finally, identifying a mutation in one person can help other family members and relatives learn their risk and take preventive measures.  

Genetic counseling is central to this process. Counsellors not only assess family history but also help interpret complex genetic results and guide decisions. They ensure that patients understand the medical and psychological implications of testing.

The future: Precision prevention

Advances in sequencing technology and data analysis are making genetic testing faster, cheaper, and more comprehensive. As India contributes more data, we can develop screening programmes tailored to local populations. Polygenic risk scores will complement single-gene, whole-genome sequencing, allowing clinicians to stratify risk more precisely and offer preventive strategies before cancer develops.

Genomics is not just about predicting disease, it is about rewriting the story. By understanding inherited risks, we can intervene early, reduce cancer incidence, and protect families across generations.

Why this matters to everyone

Even if there is family history of cancer, understanding genetics is valuable. Lifestyle factors still matter, but combining lifestyle with genetic knowledge can maximise prevention. From a public health perspective, early detection and targeted prevention reduce the burden of treatment, improve survival, and save lives.

In India, this approach is especially critical. With a large and diverse population, early-onset cancers, and limited access to healthcare in rural areas, genetics can be a tool to prioritise high-risk individuals and deploy resources effectively.

Cancer may have a genetic component, but destiny is not set in stone. Our DNA tells us about risks, but it also gives us the knowledge to act. Early screening, preventive measures, medications, and family testing can turn potential vulnerabilities into opportunities for protection. As sequencing becomes more accessible and research in India expands, the power of genomics will reach every corner of the country. We are entering an era where our inherited predisposition no longer dictates fate; it becomes a guide to early action, personalised prevention, and life-saving intervention.

As Francis Collins, leader of the Human Genome Project, famously said: “The human genome is the book of life, written in the language of DNA.” Today, we are learning to read it, understand it, and most importantly, use it to change the future of our health.